Reuters logo
BRIEF-Glenmark reports positive results from phase 3 trial of fixed-dose combination nasal spray
March 30, 2017 / 2:41 AM / 7 months ago

BRIEF-Glenmark reports positive results from phase 3 trial of fixed-dose combination nasal spray

March 30 (Reuters) - Glenmark Pharmaceuticals Ltd:

* Reports positive results from a phase 3 trial of GSP 301, mometasone/olopatadine fixed-dose combination nasal spray

* Phase 3, U.S.-based trial was a four-arm, double-blind, randomized, parallel group, active and placebo-controlled study

* Study enrolled 1,176 adults and adolescents 12 years of age and older for 14-days of twice daily treatment with GSP 301, mometasone, olopatadine or placebo.

* Says all trial arms utilized same vehicle and nasal spray delivery system

* Primary endpoint was change from baseline in average morning and evening patient-reported 12-hour reflective total nasal symptom score (RTNSS) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below